On direct compression lines for veterinary oral solids, Chuanbai Dijincao Powder Veterinary Grade API is first passed through a 40-mesh (≤420 µm) vibratory sieve and, when production area relative humidity exceeds 60%, is pre-dried in a forced-convection tray dryer at 45–55°C for 4–6 h with airflow ≤1.2 m/s before weighing. In this route the extract powder is typically incorporated at 3.0–12.0% w/w of the finished tablet core, because addition above 12% w/w reduces compactability and increases ejection force above the press limit of 1,200 N. The dry blend consists of the API with microcrystalline cellulose PH-102 at 35–55%, anhydrous dicalcium phosphate at 15–25%, crospovidone at 2–4%, sodium starch glycolate at 2–4%, and magnesium stearate at 0.5–1.0%; the lubricant is added last and mixed for only 3–5 min in a 200–600 L bin blender at 10–15 rpm to prevent shear-induced coating of API particles. Compression is run on a 16-station rotary tablet press with D-tooling, turret speed 20–40 rpm, pre-compression force 3–6 kN, and main compression force 8–16 kN; tablet hardness is maintained at 50–80 N and disintegration is controlled below 15 min according to Ph. Eur. 2.9.1. The finished product classes are uncoated or film-coated oral tablets of 150 mg, 300 mg, or 600 mg total mass for cattle, pig, and poultry routes. Compliance for the active substance and finished dosage includes VICH GL18 residual solvent testing, ICH Q3D elemental impurity screening for Class 1, 2A, and 2B elements, and assay by validated HPLC against the supplier’s marker compound; where the local veterinary pharmacopoeia monograph applies, the monograph limits for total ash, heavy metals, and microbial enumeration are also binding.

What Limits Terminal Sterilization Throughput for Aqueous Dijincao Injections?

Aqueous injection lines encounter the greatest batch-to-batch variance when Chuanbai Dijincao Powder Veterinary Grade API is dissolved at 1.0–5.0% w/v in Water for Injection at 20–30°C under high-shear mixing at 1,500–3,000 rpm for 15–30 min; the resulting solution is adjusted to pH 6.0–7.0 with 0.1 M sodium hydroxide or hydrochloric acid before sequential filtration through 1.0 µm and 0.45 µm polyethersulfone membrane capsules. The narrow processing window arises from thermal and pH sensitivity: exposure above 121°C or pH outside 5.5–7.5 precipitates hydrophobic aglycones, and the resulting filter fouling is observed as differential pressure rising from ≤0.5 bar to ≥1.2 bar within one batch, reducing throughput by 40–60% under constant pressure. The solution is degassed under vacuum at ≤−0.08 MPa for 10 min before sterile filling to prevent foam entrapment in rotary piston pumps set to 1.0–10.0 mL fill volume; terminal sterilization is performed at 121°C for 15 min with a minimum F0 of 8 recorded at the coldest point. Compliance is evaluated under Ph. Eur. 5.1.1 for sterility with a sterility assurance level of ≤10⁻⁶, Ph. Eur. 5.1.2 for bacterial endotoxins with a limit of ≤0.5 EU/mL for parenteral volumes above 10 mL or ≤0.15 EU/mL for doses below 10 mL as established in the relevant veterinary registration, and EU GMP Annex 1:2022 for Grade C background with Grade A local protection. The terminal finished product types are 5 mL, 10 mL, and 20 mL injectable solutions in amber type I glass ampoules or type II glass vials with bromobutyl rubber stoppers. Addition above 5.0% w/v is normally avoided because dynamic viscosity rises from approximately 1.5 mPa·s at 1% w/v to >4.0 mPa·s at 5% w/v, which measurably shortens 0.45 µm filter life and increases fill-weight variability above ±1.5% on rotary filling lines.

Encapsulation of the extract powder into hard gelatin or HPMC shells begins with dry granulation because direct filling at inclusion levels above 15% w/w generates fill-weight variability above ±5% on dosator-type capsule machines. Chuanbai Dijincao Powder Veterinary Grade API is dry-granulated in a roller compactor at gap 2.0–3.0 mm, roll speed 8–14 rpm, and specific roll force 4–8 kN/cm; ribbons are milled through 0.8–1.25 mm screen to produce granules with bulk density 0.55–0.75 g/cm³ and Hausner ratio 1.10–1.25. The API is incorporated at 5.0–25.0% w/w of the granulate, with the upper boundary set by hygroscopic uptake: at 25°C/60% RH, moisture above 6.0% w/w causes delayed dissolution and capsule shell cracking during long-term stability. Filling is performed on a 4,000–8,000 capsules/h intermittent-motion machine with tamping pin stations adjusted to produce capsule fill weight 250–500 mg; weight uniformity is tested according to Ph. Eur. 2.9.5 or USP <905>, and dissolution is measured in 900 mL of 0.1 M hydrochloric acid at 37°C and 50 rpm using Ph. Eur. 2.9.3 apparatus 2. Compliance also includes ICH Q3C residual solvent evaluation for the granulation solvent if a hydroalcoholic binder is used, and microbial enumeration limits under Ph. Eur. 5.1.4 category 3B for oral products. The terminal finished product types are hard gelatin capsules in sizes 0, 1, or 2, with a moisture-stable HPMC shell variant for companion animal markets where storage at 30°C/65% RH is required for 24 months.

Feed Premix Homogeneity and Particle-Size-Dependent Segregation

In medicated feed premix manufacturing, Chuanbai Dijincao Powder Veterinary Grade API is diluted by geometric addition into a carrier at 0.05–1.0% w/w of the final premix, then the premix is incorporated into complete feed at 0.5–2.0 kg/tonne, yielding an active substance carry-through of 0.5–10 g/tonne depending on registered feed indication. Production uses a horizontal ribbon blender of 300–1,000 L working volume, agitator speed 20–40 rpm, and blending time 10–20 min; blend uniformity is evaluated at 10 sampling points by HPLC and is acceptable when relative standard deviation is ≤5.0% according to ISO 6497:2002 or equivalent. Segregation control depends on the particle size match between API and carrier: a D50 of 120–180 µm in the extract powder reduces percolation through 600–1,200 µm maize starch or limestone carriers, whereas D50 below 80 µm increases dusting and static adhesion to stainless steel surfaces. The downstream process includes post-blending sizing through a 1.0 mm screen and packaging into 1 kg, 5 kg, or 25 kg aluminum-lined bags using heat-seal closure to limit moisture ingress below 60% RH. Terminal product types are medicated feed premix, top-dress powder, and oral powder for administration after mixing in feed. Regulatory compliance includes FAMI-QS certification for specialty feed ingredients, 21 CFR 225 current good manufacturing practice for medicated feeds, EU Regulation 2019/6 Article 106 conditions for veterinary prescription feed additives, and mycotoxin screening under Commission Regulation (EC) No 401/2006 as updated by (EU) 2023/1753. Finished feed recovery of the API is controlled at 90–110% of label claim with homogenous distribution demonstrated before batch release.

When the API Is Pre-Dissolved Before Incorporation into Acidified Oral Vehicles

When the extract powder is pre-dissolved for oral drench solutions, Chuanbai Dijincao Powder Veterinary Grade API is first dispersed in 10–15% propylene glycol or glycerin at 30–35°C under low-speed agitation for 20 min, then diluted with purified water to a final API concentration of 0.5–2.0% w/v. The pre-dispersion step is operationally mandatory because direct powder addition to acidified vehicles below pH 4.0 causes immediate agglomeration of polysaccharide and proteinaceous fractions, observed on production lines as a non-dispersible film on stainless steel tank walls and an increase in residue after 100 µm in-line screening above 0.5% of batch mass. Preservative systems are selected from methyl paraben 0.1% plus propyl paraben 0.02%, or sodium benzoate 0.1% with potassium sorbate 0.05%; preservative efficacy is verified under Ph. Eur. 5.1.3. The final solution is filled into 100 mL, 250 mL, or 1 L HDPE bottles using a 12-head flowmeter filler with fill accuracy ±1.0% and torque-sealed closures. Terminal finished product types are oral drench solutions and oral suspensions for cattle and swine. Industry compliance is anchored to VICH GL18 for residual solvents, Ph. Eur. 5.1.3 for antimicrobial preservation, and stability evaluation at ICH Zone IVb conditions of 30°C/65% RH for 24 months. Published data for this specific extract in oral vehicles below pH 3.5 is limited; therefore, pilot-scale batches are validated only at pH 4.0–6.5 before scale-up.

Wet Granulation Endpoint Control in a Botanical Extract Matrix

Granule production for reconstitution into drinking water or oral paste uses wet granulation when direct compression is not viable because the powder flow index falls below 4 mm at addition ratios above 12% w/w. Chuanbai Dijincao Powder Veterinary Grade API is granulated with a binder solution of 5% w/v povidone K30 in purified water or a hydroalcoholic vehicle, sprayed at 80–120 g/min in a top-spray fluidised bed at inlet air temperature 55–65°C, product temperature 30–40°C, and exhaust relative humidity below 40% to avoid defluidization. The API is incorporated at 5.0–20.0% w/w of the dry granule mass; the lower boundary is set by dose uniformity in small-volume dosing cups, while the upper boundary is set by a granule bulk density drop below 0.45 g/cm³ and an increase in friability above 1.0%. Drying endpoint is not time-based: final moisture is measured by USP <921> Method Ia at 105°C to 3.5–5.5%, and a deviation of ±0.5% moisture shifts the particle size D50 by more than 30 µm, increasing fill-weight variability on vertical form-fill-seal equipment above ±2.5%. Terminal finished product types are 10 g, 20 g, and 50 g sachets or jars for reconstitution as oral solution or suspension. The granulation operation follows EU GMP Part II for active substances and 21 CFR 211 subpart E for component and drug product container control; cleaning validation is performed to a maximum allowable carryover of 10 ppm with swab limits derived from the health-based exposure limit approach described in the EMA guideline on setting health-based limits for risk identification in manufacturing. Sieve analysis is performed using Ph. Eur. 2.9.38 or USP <786> with a nested sieve stack of 75 µm, 150 µm, 250 µm, 425 µm, and 850 µm to confirm D10/D50/D90 ranges before release.